Table 1 Patients’ characteristics
| ET | PV | Total | |
|---|---|---|---|
| N, (%) | 305 (64) | 172 (36) | 477 |
| Sex (M/F), n (%) | 112/193 (37/63) | 91/81 (53/47) | 203/274 (43/57) |
|
Age, years, median (5th–95th percentiles) | 58.0 (27.7–83.0) | 58.3 (35.5–82.0) | 58.0 (28.3–82.7) |
| Mutational status, n (%) | |||
| Triple negatives | 57 (18) | 9 (5) | 66 (14) |
| CALR | 44 (14) | 0 (0) | 44 (9) |
| MPLW515L/K | 14 (5) | 0 (0) | 14 (3) |
| JAK2V617F hetero | 176 (58) | 95 (55) | 271 (57) |
| JAK2V617F homo | 14 (5) | 64 (37) | 78 (16) |
| JAK2 exon 12 mutation | 0 (0) | 4 (2) | 4 (1) |
|
Hs-CRP, mg/L, median (5th–95th percentiles) | 0.83 (0.03–7.96) | 0.87 (0.03–6.43) | 0.83 (0.03–7.53) |
|
PTX3, ng/mL, median (5th–95th percentiles) | 4.55 (0.58–14.95) | 5.88 (0.42–22.96) | 4.83 (0.54–18.48) |